This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Depardieu, F.
Right arrow Articles by Courvalin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Depardieu, F.
Right arrow Articles by Courvalin, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 319-323, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.319-323.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Mutation in 23S rRNA Responsible for Resistance to 16-Membered Macrolides and Streptogramins in Streptococcus pneumoniae

Florence Depardieu* and Patrice Courvalin

Unité des Agents Antibactériens, Institut Pasteur, 75724 Paris Cedex 15, France

Received 3 July 2000/Returned for modification 11 September 2000/Accepted 11 October 2000


    ABSTRACT
Top
Abstract
Text
References

Streptococcus pneumoniae clinical isolate BM4455 was resistant to 16-membered macrolides and to streptogramins. This unusual resistance phenotype was due to an A2062C (Escherichia coli numbering) mutation in domain V of the four copies of 23S rRNA.


    TEXT
Top
Abstract
Text
References

Macrolide and lincosamide antibiotics exhibit high activity against streptococci and are among the drugs that can be used for the treatment of infections due to Streptococcus pneumoniae (10). The macrolides are largely prescribed for empiric therapy of community-acquired respiratory tract infections and may be useful in case of intolerance or resistance to beta -lactams. In France, oral streptogramins are the second line treatment in the macrolide, lincosamide, streptogramin (MLS) group of antibiotics, in which they replace erythromycin and related macrolides in case of resistance of S. pneumoniae to macrolides (11). The streptogramin antibiotics produced by Streptomyces pristinaespiralis contain two active components, A and B (II and I in pristinamycin, M and S in virginiamycin, and the semisynthetic derivatives dalfopristin and quinupristin in Synercid), that inhibit peptide elongation synergistically; individually they are bacteriostatic, whereas together they can be bacteriocidal. The presence of the A component strongly enhances ribosomal binding of the B component (19). The prevalence of macrolide-resistant strains of S. pneumoniae has increased during the last 10 years (17, 22). There is, thus, a need for alternative drugs. The ketolides, such as telithromycin, constitute a new semisynthetic 14-membered macrolide class of antimicrobial agents (8). Telithromycin is a 3-keto derivative of clarithromycin. The ketolides have the same antibacterial spectrum as macrolides but also display good activity against erythromycin-resistant isolates of gram-positive cocci (8).

The macrolide, lincosamide, and streptogramin B antibiotics (MLSB) are three chemically distinct but functionally related drug classes. They act by binding to the 50S subunit of bacterial ribosomes and inhibit protein synthesis by blocking elongation of the nascent peptide chain (2, 10).

Resistance to macrolides in S. pneumoniae is due to two mechanisms: target site modification or active efflux. Target modification is secondary to acquisition of an erm gene which encodes an enzyme that methylates a specific adenine residue (A2058) in 23S rRNA (Fig. 1) (10). This alteration induces a conformational change in the 50S ribosomal subunit that blocks binding of the MLSB to the ribosome (10). Expression of resistance can be inducible or constitutive. Streptococci, as opposed to staphylococci, are cross-resistant to 14-, 15-, and 16-membered MLSB whether resistance is inducible or constitutive. Streptogramins A are not affected, and synergy between the two components of streptogramins against MLSB-resistant strains is maintained. Thus, in streptococci, constitutive resistance cannot be distinguished from inducible resistance on the sole basis of elevated MICs of erythromycin and lincomycin (21). The high prevalence of the MLSB-inducible phenotype in S. pneumoniae explains why weak inducers like the ketolides are active against most of the isolates of this species.


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 1.   Secondary structure of the peptidyl transferase loop in domain V of 23S rRNA. The mutated position in S. pneumoniae BM4455 is indicated by a square. The positions of the other binding sites of streptogramins (m2A2503-U2504) are indicated by a circle. Nucleotide sequence and numbering are those of E. coli 23S rRNA, and the corresponding S. pneumoniae numbering is given in parentheses.

The second resistance mechanism, macrolide-specific efflux from the cells, is effected by a membrane protein encoded by the mef gene (25). This leads to the M phenotype, which is resistance to 14- and 15-membered macrolides and susceptibility to 16-membered macrolides, ketolides, lincosamides, and streptogramins. The mef gene is the most common macrolide resistance determinant among S. pneumoniae isolates in the United States, whereas erm is more prevalent in Europe (17, 22).

Recently, two other mechanisms associated with unusual resistance phenotypes to MLS antibiotics have been identified in clinical isolates of S. pneumoniae. Macrolide-streptogramin resistance is due to a 3-amino-acid substitution, whereas further resistance to ketolides is due to a 6-amino-acid insertion in a highly conserved region of ribosomal protein L4 (63KPWRQKGTGRAR74 [S. pneumoniae numbering]) (A. Tait-Kamradt, T. Davies, L. Brennan, F. Depardieu, P. Courvalin, J. Duignan, J. Petitpas, L. Wondrack, M. Jacobs, P. Appelbaum, and J. Sutcliffe, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. LB-8, 1999). The macrolide-lincosamide resistance phenotype observed in clinical isolates from the United States or in laboratory mutants is due to an A2059G (Escherichia coli numbering) change in two, three, or four copies of 23S rRNA (26). A gene dosage effect on the level of macrolide and lincosamide resistance was observed in isogenic strains depending upon the number of mutated rrl alleles.

S. pneumoniae BM4455, of capsular serovar 18F, was isolated in 1988 in France from a blood culture (6) and had a new resistance phenotype (Table 1). There was a dissociation between resistance to 16-membered macrolides and susceptibility to 14- and 15-membered macrolides associated with resistance to the two components of streptogramins. The MICs of certain MLS antibiotics for S. pneumoniae BM4455 and susceptible S. pneumoniae BM4203 and CP1000 (Table 1) were determined by agar dilution in Mueller-Hinton medium supplemented with 5% horse blood with an inoculum of 104 CFU per spot (Table 2) (3). Strain BM4455 was resistant to high levels of 16-membered macrolides and to intermediate levels of streptogramins A and B, but synergy between the two components was retained. The strain remained susceptible to the 14- and 15-membered macrolides, the ketolides, and the lincosamides.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Strains of S. pneumoniae studied


                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   MICs of antibiotics against S. pneumoniae strainsa

S. pneumoniae BM4455 was tested for the presence of known MLS resistance determinants. Attempts to amplify genomic DNA using primers specific for ermA, ermB, and ermC genes encoding an rRNA methylase; ereA and ereB specifying a macrolide esterase; mphA and mphB macrolide phosphotransferases; msrA, an ATP binding cassette-type transporter; and mefA, a proton-motive force macrolide transporter (24), were unsuccessful (data not shown).

The possibility that strain BM4455 carried mutations in ribosomal proteins L4, L16, or L22 or in 23S rRNA was explored. Ribosomal proteins L4 and L22 are involved in the binding of spiramycin to the 50S subunit of the ribosome (1, 7, 31). Proteins L16 and L22 interact with the streptogramins (4, 5). L4 and L22 bind primarily to domain I of 23S rRNA, but erythromycin resistance mutations in these proteins perturb the conformation of residues in domains II, III, and V and thereby affect the action of antibiotics known to interact with nucleotide residues in the peptidyl transferase center of domain V (7). Mutations conferring resistance to macrolides were first identified in proteins L4 and L22 of E. coli (18, 31) and subsequently in 23S rRNA (30). There is compelling evidence that the peptidyltransferase loop in domain V of 23S rRNA may contain at least part of the site at which the MLS antibiotics physically bind to the ribosome (14, 19, 30). Mutants selected for resistance to individual MLS antibiotics show changes in A2058 (E. coli numbering) and neighboring nucleotides, suggesting their involvement in the binding of these antibiotics (30).

The primers used to amplify the entire structural genes rplD, rplP, and rplV for ribosomal proteins L4, L16, and L22, respectively, and of part of rrl for domains II and V of 23S rRNA were designed complementary to conserved regions (Table 3). Amplifications were performed with total DNA of strain BM4455 as a template using Pfu polymerase (Stratagene) in a DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, Conn.) for 30 cycles. The conditions were 1 min at 95°C for denaturation, 1 min at 50°C (rplD, rplP, rplV, and rrl for domain II) or at 54°C (four alleles of rrl corresponding to domain V) for annealing, and 2 min at 72°C for elongation. The amplification products were purified, cloned into pCR-Blunt vector (Invitrogen), and sequenced by the dideoxy chain termination method using T7 DNA polymerase (T7 Sequencing kit; Pharmacia) and [alpha -35S]-dATP (Amersham Radiochemical Centre). The sequences obtained were compared with those of S. pneumoniae obtained from The Institute for Genomic Research (TIGR)'s Website (http://www.tigr.org.). No mutations were observed in the rplP and rplV genes, whereas the sequence of rplD for L4 differed by a point mutation in codon 20, leading to a Ser-to-Asn substitution (Table 3).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 3.   Oligodeoxynucleotides used and mutations in S. pneumoniae strains

Four copies of the 23S rRNA rrl gene are present in S. pneumoniae, and a strategy has been developed to amplify these copies individually for domain V (26). It consists in using primers complementary to unique sequences downstream from each rrl gene and a primer (23S rRNA-V+) common to the four alleles and complementary to a region upstream from the peptidyl transferase region in domain V (Table 3). The four rrl genes were amplified separately, the region encoding domain V was sequenced, and each copy was found to contain an A2062C (E. coli numbering) substitution. No mutations were observed in the rrl portion corresponding to domain II.

To determine if the mutations in the rplD gene for ribosomal protein L4 and in the portion of rrl corresponding to domain V of 23S rRNA were necessary and sufficient to confer the 16-membered macrolide-streptogramin (M16-S) resistance phenotype to the host, total DNA from strain BM4455 or the PCR products corresponding to the rplD gene and domain V of the rrl gene were introduced into S. pneumoniae CP1000 by transformation (Table 1). Chromosomal or amplified DNA was added to competent cells of CP1000, and the mixture was incubated at 37°C until the optical density at 550 nm reached 0.2. The bacteria were then plated onto horse blood agar and incubated at 37°C for 2 h without antibiotic. Transformants were selected with spiramycin at 10 µg/ml and 60 µg/ml or pristinamycin at 1 µg/ml by the overlay procedure and incubated 24 to 48 h at 37°C in an atmosphere enriched with 5% CO2. Transformants were obtained only with chromosomal DNA or with the 1,013-bp rrl PCR fragment of domain V containing the A2062C mutation and on spiramycin (10 µg/ml). Their phenotype was indistinguishable from that of the donor strain BM4455 (Table 1). Experiments performed with the 855-bp rplD PCR product containing the G-to-A substitution at position 59 (Table 3) did not yield any transformant. The four rrl alleles corresponding to domain V and the rplD gene of transformants BM4456 and BM4457 obtained with total DNA or the rrl PCR product of domain V (Table 1), respectively, were amplified and sequenced as described above. The two transformants were found to harbor the same A2062C mutation in the four rrl copies as in the donor but not the substitution in the rplD gene for ribosomal protein L4 (Table 3). The MICs of various MLS antibiotics against the transformants were determined and found to be similar to those against the wild strain (Table 2). Taken together these data indicate that the mutation in the four rrl genes corresponding to domain V is solely responsible for resistance to 16-membered macrolides and to streptogramins. Gene conversion could be responsible for the presence of the A2062C mutation in the four rrl copies (9).

To the best of our knowledge, a single example of mutation at position 2062 of 23S rRNA has been reported. A chloramphenicol-resistant mutant was isolated in Halobacterium halobium, which possesses a single copy of 23S rRNA, that contained an A-to-C substitution at position 2062 (E. coli numbering) in domain V (13). The target site for macrolides lies within 23S rRNA at the peptidyltransferase center of the 50S subunit (Fig. 1). The peptidyltransferase activity is associated with the central loop of domain V, where macrolides make several contacts with the rRNA (14). Recently, the binding sites of streptogramins B in E. coli were localized by UV-induced modifications at positions A2503-U2504 and G2061-A2062 in the peptidyltransferase loop (Fig. 1) (19, 20). Mutation at position 2062 of 23S rRNA may therefore prevent binding of pristinamycin I and account for resistance in strain BM4455 (Fig. 1).

Mutations at A2058 presumably perturb the site were the MLS drugs interact with the ribosome and thereby affect their binding in a manner similar to methylation at this position (23). In Helicobacter pylori, clarithromycin resistance is due to mutations at position 2058 or 2059 in the 23S rRNA (28). Mutations at position 2058 confer an MLSB phenotype with high-level clarithromycin resistance, an A-to-G substitution being the most common in clinical isolates (29). Mutations at position 2059 confer a lower level of resistance to clarithromycin and no resistance to the streptogramins (16). Mycoplasma pneumoniae displays phenotypes similar to those of H. pylori following A2058G and A2059G mutations, and it has been shown that the G2059 mutant is more resistant to 16-membered macrolides such as tylosin and spiramycin (12). These results could reflect subtle differences in the mode of interaction of 14- and 16-membered macrolides in the 2058 region of 23S rRNA (14). Erythromycin-resistant mutants that remain susceptible to spiramycin also support the notion that the ribosome binding sites for the two groups of macrolides are not identical (1). In addition, the drugs with 16 atoms are much larger than those with 14 atoms, and the number of sugar residues also differs. Together these observations could explain the dissociated resistance between 16- or 14- and 15-membered macrolides.

In conclusion, we have shown that an A2062C mutation in 23S rRNA confers M16-S resistance in S. pneumoniae. With the emergence of new resistance mechanisms, it seems advisable to test in vitro the activity of one member each of the 14-, 15-, and 16-membered macrolide, ketolide, lincosamide, and streptogramin class of drugs.


    ACKNOWLEDGMENTS

This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases.

We thank R. Carnahan for having initiated this work.


    FOOTNOTES

* Corresponding author. Mailing address: Unité des Agents Antibactériens, Institut Pasteur, 25, rue du Docteur Roux, 75724 Paris Cedex 15, France. Phone: (33) (1) 45 68 83 21. Fax: (33) (1) 45 68 83 19. E-mail: fdepard{at}pasteur.fr.


    REFERENCES
Top
Abstract
Text
References

1. Arevalo, M. A., F. Tejedor, F. Polo, and J. P. Ballesta. 1988. Protein components of the erythromycin binding site in bacterial ribosomes. J. Biol. Chem. 263:58-63[Abstract/Free Full Text].
2. Brisson-Noel, A., P. Trieu-Cuot, and P. Courvalin. 1988. Mechanism of action of spiramycin and other macrolides. J. Antimicrob. Chemother. 22(Suppl. B):13-23.
3. Comité de l'Antibiogramme de la Société Française de Microbiologie. 1996. Zone sizes and breakpoints for non-fastidious organisms. Clin. Microbiol. Infect. 2(Suppl.):1-49[Medline].
4. de Bethune, M. P., and K. H. Nierhaus. 1978. Characterisation of the binding of virginiamycin S to Escherichia coli ribosomes. Eur. J. Biochem. 86:187-191[Medline].
5. Di Giambattista, M., G. Chinali, and C. Cocito. 1989. The molecular basis of the inhibitory activities of type A and type B synergimycins and related antibiotics on ribosomes. J. Antimicrob. Chemother. 24:485-507[Free Full Text].
6. Emond, J. P., A. Fremaux, A. Dublanchet, G. Sissia, P. Geslin, A. Sedalian, and G. Lionsquy. 1989. Resistance of two strains of Streptococcus pneumoniae to pristinamycin associated with 16-membered macrolides. Pathol. Biol. 37:791-792[Medline].
7. Gregory, S. T., and A. E. Dahlberg. 1999. Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA. J. Mol. Biol. 289:827-834[CrossRef][Medline].
8. Jones, R. N., and D. J. Biedenbach. 1997. Antimicrobial activity of RU-66647, a new ketolide. Diagn. Microbiol. Infect. Dis. 27:7-12[CrossRef][Medline].
9. Kobayashi, I. 1992. Mechanisms for gene conversion and homologous recombination: the double-strand break repair model and the successive half crossing-over model. Adv. Biophys. 28:81-133[CrossRef][Medline].
10. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemother. 35:1267-1272[Free Full Text].
11. Leclercq, R., and P. Courvalin. 1998. Streptogramins: an answer to antibiotic resistance in gram-positive bacteria. Lancet 352:591-592[CrossRef][Medline].
12. Lucier, T. S., K. Heitzman, S. K. Liu, and P. C. Hu. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 39:2770-2773[Abstract].
13. Mankin, A. S., and R. A. Garrett. 1991. Chloramphenicol resistance mutations in the single 23S rRNA gene of the archaeon Halobacterium halobium. J. Bacteriol. 173:3559-3563[Abstract/Free Full Text].
14. Moazed, D., and H. F. Noller. 1987. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie 69:879-884[Medline].
15. Morrison, D. A., M. C. Trombe, M. K. Hayden, G. A. Waszak, and J. D. Chen. 1984. Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence, using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAMb1. J. Bacteriol. 159:870-876[Abstract/Free Full Text].
16. Occhialini, A., M. Urdaci, F. Doucet-Populaire, C. M. Bebear, H. Lamouliatte, and F. Megraud. 1997. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob. Agents Chemother. 41:2724-2728[Abstract].
17. Oster, P., A. Zanchi, S. Cresti, M. Lattanzi, F. Montagnani, C. Cellesi, and G. M. Rossolini. 1999. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob. Agents Chemother. 43:2510-2512[Abstract/Free Full Text].
18. Pardo, D., and R. Rosset. 1977. Properties of ribosomes from erythromycin resistant mutants of Escherichia coli. Mol. Gen. Genet. 156:267-271[CrossRef][Medline].
19. Porse, B. T., and R. A. Garrett. 1999. Sites of interaction of streptogramin A and B antibiotics in the peptidyl transferase loop of 23 S rRNA and the synergism of their inhibitory mechanisms. J. Mol. Biol. 286:375-387[CrossRef][Medline].
20. Porse, B. T., S. V. Kirillov, M. J. Awayez, and R. A. Garrett. 1999. UV-induced modifications in the peptidyl transferase loop of 23S rRNA dependent on binding of the streptogramin B antibiotic, pristinamycin IA. RNA 5:585-595[Abstract].
21. Rosato, A., H. Vicarini, and R. Leclercq. 1999. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J. Antimicrob. Chemother. 43:559-562[Abstract/Free Full Text].
22. Shortridge, V. D., G. V. Doern, A. B. Brueggemann, J. M. Beyer, and R. K. Flamm. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29:1186-1188[CrossRef][Medline].
23. Sigmund, C. D., M. Ettayebi, and E. A. Morgan. 1984. Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res. 12:4653-4663[Abstract/Free Full Text].
24. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566[Abstract].
25. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255[Abstract].
26. Tait-Kamradt, A., T. Davies, M. Cronan, M. R. Jacobs, P. C. Appelbaum, and J. Sutcliffe. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125[Abstract/Free Full Text].
27. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510[Abstract].
28. Versalovic, J., D. Shortridge, K. Kibler, M. V. Griffy, J. Beyer, R. K. Flamm, S. K. Tanaka, D. Y. Graham, and M. F. Go. 1996. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40:477-480[Abstract].
29. Wang, G., and D. E. Taylor. 1998. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob. Agents Chemother. 42:1952-1958[Abstract/Free Full Text].
30. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. Antimicrob. Agents Chemother. 39:577-585[Medline].
31. Wittmann, H. G., G. Stoffler, D. Apirion, L. Rosen, K. Tanaka, M. Tamaki, R. Takata, S. Dekio, and E. Otaka. 1973. Biochemical and genetic studies on two different types of erythromycin resistant mutants of Escherichia coli with altered ribosomal proteins. Mol. Gen. Genet. 127:175-189[CrossRef][Medline].

Antimicrobial Agents and Chemotherapy, January 2001, p. 319-323, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.319-323.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kastrin, T., Gubina, M., Paragi, M., Kolman, J., Cizman, M., Kraigher, A., Ribic, H., Sadowy, E., Hryniewicz, W. (2008). Macrolide resistance among invasive Streptococcus pneumoniae in Slovenia. J Antimicrob Chemother 62: 628-629 [Full Text]  
  • Wierzbowski, A. K., Nichol, K., Laing, N., Hisanaga, T., Nikulin, A., Karlowsky, J. A., Hoban, D. J., Zhanel, G. G. (2007). Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). J Antimicrob Chemother 60: 733-740 [Abstract] [Full Text]  
  • van der Linden, M., Al-Lahham, A., Haupts, S., Reinert, R. R. (2007). Clonal Spread of mef-Positive Macrolide-Resistant Streptococcus pneumoniae Isolates Causing Invasive Disease in Adults in Germany. Antimicrob. Agents Chemother. 51: 1830-1834 [Abstract] [Full Text]  
  • Cattoir, V., Merabet, L., Legrand, P., Soussy, C.-J., Leclercq, R. (2007). Emergence of a Streptococcus pneumoniae isolate resistant to streptogramins by mutation in ribosomal protein L22 during pristinamycin therapy of pneumococcal pneumonia. J Antimicrob Chemother 59: 1010-1012 [Abstract] [Full Text]  
  • Obert, C. A., Miller, M. L., Montgomery, J., Adamkiewicz, T., Tuomanen, E. I. (2007). Quinupristin-Dalfopristin Nonsusceptibility in Pneumococci from Sickle Cell Disease Patients. Antimicrob. Agents Chemother. 51: 386-389 [Abstract] [Full Text]  
  • Zeng, X., Kong, F., Wang, H., Darbar, A., Gilbert, G. L. (2006). Simultaneous Detection of Nine Antibiotic Resistance-Related Genes in Streptococcus agalactiae Using Multiplex PCR and Reverse Line Blot Hybridization Assay. Antimicrob. Agents Chemother. 50: 204-209 [Abstract] [Full Text]  
  • Malhotra-Kumar, S., Lammens, C., Piessens, J., Goossens, H. (2005). Multiplex PCR for Simultaneous Detection of Macrolide and Tetracycline Resistance Determinants in Streptococci. Antimicrob. Agents Chemother. 49: 4798-4800 [Abstract] [Full Text]  
  • Carsenti-Dellamonica, H., Galimand, M., Vandenbos, F., Pradier, C., Roger, P. M., Dunais, B., Sabah, M., Mancini, G., Dellamonica, P. (2005). In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides. J Antimicrob Chemother 56: 633-642 [Abstract] [Full Text]  
  • Gregory, S. T., Carr, J. F., Rodriguez-Correa, D., Dahlberg, A. E. (2005). Mutational Analysis of 16S and 23S rRNA Genes of Thermus thermophilus. J. Bacteriol. 187: 4804-4812 [Abstract] [Full Text]  
  • Gibreel, A., Kos, V. N., Keelan, M., Trieber, C. A., Levesque, S., Michaud, S., Taylor, D. E. (2005). Macrolide Resistance in Campylobacter jejuni and Campylobacter coli: Molecular Mechanism and Stability of the Resistance Phenotype. Antimicrob. Agents Chemother. 49: 2753-2759 [Abstract] [Full Text]  
  • Reinert, R. R., Reinert, S., van der Linden, M., Cil, M. Y., Al-Lahham, A., Appelbaum, P. (2005). Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003. Antimicrob. Agents Chemother. 49: 2903-2913 [Abstract] [Full Text]  
  • Davies, T. A., Bush, K., Sahm, D., Evangelista, A. (2005). Predominance of 23S rRNA Mutants among Non-Erm, Non-Mef Macrolide-Resistant Clinical Isolates of Streptococcus pneumoniae Collected in the United States in 1999-2000. Antimicrob. Agents Chemother. 49: 3031-3033 [Abstract] [Full Text]  
  • Kosowska, K., Hoellman, D. B., Lin, G., Clark, C., Credito, K., McGhee, P., Dewasse, B., Bozdogan, B., Shapiro, S., Appelbaum, P. C. (2005). Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 1932-1942 [Abstract] [Full Text]  
  • Reinert, R. R., Ringelstein, A., van der Linden, M., Cil, M. Y., Al-Lahham, A., Schmitz, F.-J. (2005). Molecular Epidemiology of Macrolide-Resistant Streptococcus pneumoniae Isolates in Europe. J. Clin. Microbiol. 43: 1294-1300 [Abstract] [Full Text]  
  • Farrell, D. J., Morrissey, I., Bakker, S., Buckridge, S., Felmingham, D. (2004). In Vitro Activities of Telithromycin, Linezolid, and Quinupristin-Dalfopristin against Streptococcus pneumoniae with Macrolide Resistance Due to Ribosomal Mutations. Antimicrob. Agents Chemother. 48: 3169-3171 [Abstract] [Full Text]  
  • Petropoulos, A. D., Xaplanteri, M. A., Dinos, G. P., Wilson, D. N., Kalpaxis, D. L. (2004). Polyamines Affect Diversely the Antibiotic Potency: INSIGHT GAINED FROM KINETIC STUDIES OF THE BLASTICIDIN S AND SPIRAMYCIN INTERACTIONS WITH FUNCTIONAL RIBOSOMES. J. Biol. Chem. 279: 26518-26525 [Abstract] [Full Text]  
  • Reinert, R. R. (2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 53: 918-927 [Abstract] [Full Text]  
  • Cochella, L., Green, R. (2004). Isolation of antibiotic resistance mutations in the rRNA by using an in vitro selection system. Proc. Natl. Acad. Sci. USA 101: 3786-3791 [Abstract] [Full Text]  
  • Pereyre, S., Guyot, C., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2004). In Vitro Selection and Characterization of Resistance to Macrolides and Related Antibiotics in Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 48: 460-465 [Abstract] [Full Text]  
  • Waites, K. B., Jones, K. E., Kim, K. H., Moser, S. A., Johnson, C. N., Hollingshead, S. K., Kang, E.-S., Hong, K. S., Benjamin, W. H. Jr. (2003). Dissemination of Macrolide-Resistant Streptococcus pneumoniae Isolates Containing Both erm(B) and mef(A) in South Korea. J. Clin. Microbiol. 41: 5787-5791 [Abstract] [Full Text]  
  • Walsh, F., Willcock, J., Amyes, S. (2003). High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother 52: 345-353 [Abstract] [Full Text]  
  • Montanari, M. P., Cochetti, I., Mingoia, M., Varaldo, P. E. (2003). Phenotypic and Molecular Characterization of Tetracycline- and Erythromycin-Resistant Strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2236-2241 [Abstract] [Full Text]  
  • Reinert, R. R., Wild, A., Appelbaum, P., Lutticken, R., Cil, M. Y., Al-Lahham, A. (2003). Ribosomal Mutations Conferring Resistance to Macrolides in Streptococcus pneumoniae Clinical Strains Isolated in Germany. Antimicrob. Agents Chemother. 47: 2319-2322 [Abstract] [Full Text]  
  • Farrell, D. J., Douthwaite, S., Morrissey, I., Bakker, S., Poehlsgaard, J., Jakobsen, L., Felmingham, D. (2003). Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob. Agents Chemother. 47: 1777-1783 [Abstract] [Full Text]  
  • Peric, M., Bozdogan, B., Jacobs, M. R., Appelbaum, P. C. (2003). Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical Isolates. Antimicrob. Agents Chemother. 47: 1017-1022 [Abstract] [Full Text]  
  • Reinert, R. R., Lutticken, R., Bryskier, A., Al-Lahham, A. (2003). Macrolide-Resistant Streptococcus pneumoniae and Streptococcus pyogenes in the Pediatric Population in Germany during 2000-2001. Antimicrob. Agents Chemother. 47: 489-493 [Abstract] [Full Text]  
  • Montanari, M. P., Mingoia, M., Cochetti, I., Varaldo, P. E. (2003). Phenotypes and Genotypes of Erythromycin-Resistant Pneumococci in Italy. J. Clin. Microbiol. 41: 428-431 [Abstract] [Full Text]  
  • Giovanetti, E., Brenciani, A., Burioni, R., Varaldo, P. E. (2002). A Novel Efflux System in Inducibly Erythromycin-Resistant Strains of Streptococcus pyogenes. Antimicrob. Agents Chemother. 46: 3750-3755 [Abstract] [Full Text]  
  • Leclercq, R., Courvalin, P. (2002). Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 2727-2734 [Full Text]  
  • Kozlov, R. S., Bogdanovitch, T. M., Appelbaum, P. C., Ednie, L., Stratchounski, L. S., Jacobs, M. R., Bozdogan, B. (2002). Antistreptococcal Activity of Telithromycin Compared with Seven Other Drugs in Relation to Macrolide Resistance Mechanisms in Russia. Antimicrob. Agents Chemother. 46: 2963-2968 [Abstract] [Full Text]  
  • Ng, L.-K., Martin, I., Liu, G., Bryden, L. (2002). Mutation in 23S rRNA Associated with Macrolide Resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 46: 3020-3025 [Abstract] [Full Text]  
  • Prunier, A.-L., Malbruny, B., Tande, D., Picard, B., Leclercq, R. (2002). Clinical Isolates of Staphylococcus aureus with Ribosomal Mutations Conferring Resistance to Macrolides. Antimicrob. Agents Chemother. 46: 3054-3056 [Abstract] [Full Text]  
  • Malbruny, B., Canu, A., Bozdogan, B., Fantin, B., Zarrouk, V., Dutka-Malen, S., Feger, C., Leclercq, R. (2002). Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein in Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 2200-2207 [Abstract] [Full Text]  
  • Malbruny, B., Nagai, K., Coquemont, M., Bozdogan, B., Andrasevic, A. T., Hupkova, H., Leclercq, R., Appelbaum, P. C. (2002). Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother 49: 935-939 [Abstract] [Full Text]  
  • Pihlajamaki, M., Kaijalainen, T., Huovinen, P., Jalava, J., the Finnish Study Group for Antimicrobial Resistan, (2002). Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J Antimicrob Chemother 49: 785-792 [Abstract] [Full Text]  
  • Pihlajamaki, M., Kataja, J., Seppala, H., Elliot, J., Leinonen, M., Huovinen, P., Jalava, J. (2002). Ribosomal Mutations in Streptococcus pneumoniae Clinical Isolates. Antimicrob. Agents Chemother. 46: 654-658 [Abstract] [Full Text]  
  • Shortridge, V. D., Zhong, P., Cao, Z., Beyer, J. M., Almer, L. S., Ramer, N. C., Doktor, S. Z., Flamm, R. K. (2002). Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci. Antimicrob. Agents Chemother. 46: 783-786 [Abstract] [Full Text]  
  • Musher, D. M., Dowell, M. E., Shortridge, V. D., Flamm, R. K., Jorgensen, J. H., Le Magueres, P., Krause, K. L. (2002). Emergence of Macrolide Resistance during Treatment of Pneumococcal Pneumonia. NEJM 346: 630-631 [Full Text]  
  • Canu, A., Malbruny, B., Coquemont, M., Davies, T. A., Appelbaum, P. C., Leclercq, R. (2002). Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 125-131 [Abstract] [Full Text]  
  • Farrell, D. J., Morrissey, I., Bakker, S., Felmingham, D. (2001). Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother 48: 541-544 [Abstract] [Full Text]  
  • Furneri, P. M., Rappazzo, G., Musumarra, M. P., Di Pietro, P., Catania, L. S., Roccasalva, L. S. (2001). Two New Point Mutations at A2062 Associated with Resistance to 16-Membered Macrolide Antibiotics in Mutant Strains of Mycoplasma hominis. Antimicrob. Agents Chemother. 45: 2958-2960 [Abstract] [Full Text]  
  • Fitoussi, F., Loukil, C., Gros, I., Clermont, O., Mariani, P., Bonacorsi, S., Le Thomas, I., Deforche, D., Bingen, E. (2001). Mechanisms of Macrolide Resistance in Clinical Group B Streptococci Isolated in France. Antimicrob. Agents Chemother. 45: 1889-1891 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Depardieu, F.
Right arrow Articles by Courvalin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Depardieu, F.
Right arrow Articles by Courvalin, P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»